ALPRE

FR0010169920

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 08:11:36 14/05/2024 pm IST			5-day change	1st Jan Change
6.9 ^EUR	-1.43%		-8.00%	+21.05%

2023	Predilife: a project accredited by Finance Innovation	CF
2023	Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Predilife S.A. has completed an IPO in the amount of €3.591232 million.

December 18, 2018 at 10:30 am IST

Predilife S.A. has completed an IPO in the amount of €3.591232 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 386,154 PriceRange: €9.3

Latest news about PREDILIFE

Predilife: a project accredited by Finance Innovation	04/23/04	CF
Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	15/23/15	CI
Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Predilife: predictive assessment contract with Colas	12/23/12	CF
Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	25/22/25	CI
Predilife Taps Eurofins to Conduct Genetic Testing of Saliva Samples	20/21/20	MT
Global markets live: Valneva, Glencore, Facebook, Roche, Hertz...	18/21/18
Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	28/21/28	CI
Global markets live: Valneva,Boeing, Facebook, Kubota, Otis...	23/21/23
Global markets live: Credit Suisse, Apple, Verizon...	03/21/03
Predilife S.A. and Institut Curie Announce Partnership Covering Genetic Analyses for Mammorisk, the Next-Generation Test Predicting the Risk of Breast Cancer	06/19/06	CI
Predilife S.A. has completed an IPO in the amount of €3.591232 million.	18/18/18	CI
Predilife S.A. has filed an IPO in the amount of €7.006296 million.	04/18/04	CI

PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women,over 300,000 French women and 500,000 English.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
PREDILIFE	+21.05%	27.96M
EXACT SCIENCES CORPORATION	-25.89%	10.26B
IOVANCE BIOTHERAPEUTICS, INC.	+35.85%	3.04B
GUARDANT HEALTH, INC.	-4.99%	2.94B
BGI GENOMICS CO., LTD.	-12.92%	2.19B
VERACYTE, INC.	-14.72%	1.72B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+66.03%	1.4B
CAREDX, INC	+30.25%	780M
SEEGENE, INC.	-4.59%	736M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-16.43%	560M

Bio Diagnostics & Testing

PREDILIFE

Equities

ALPRE

FR0010169920

Biotechnology & Medical Research

Predilife S.A. has completed an IPO in the amount of €3.591232 million.

Latest news about PREDILIFE

Chart PREDILIFE

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Bio Diagnostics & Testing